+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H2 2018

  • ID: 4667892
  • Drug Pipelines
  • November 2018
  • Region: Global
  • 185 Pages
  • Global Markets Direct
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • AbbVie Inc
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Han Wha Pharma Co Ltd
  • Japan Tobacco Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H2 2018

Summary

According to the recently published report 'Tyrosine Protein Kinase JAK1 - Pipeline Review, H2 2018'; Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 33 molecules.

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body.

The report 'Tyrosine Protein Kinase JAK1 - Pipeline Review, H2 2018' outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 2, 6, 11, 12 and 2 respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Respiratory, Hematological Disorders and Ophthalmology which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Alopecia, Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Vitiligo, Psoriasis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Diffuse Large B-Cell Lymphoma, Psoriatic Arthritis, Ankylosing Spondylitis (Bekhterev's Disease), B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphomas (PTCL), Relapsed Multiple Myeloma, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Androgenic Alopecia, Arthritis, Auto Inflammatory Disease, B-Cell Chronic Lymphocytic Leukemia, Breast Cancer, Bronchiolitis Obliterans, Cancer Anorexia-Cachexia Syndrome, Chronic Asthma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Dermatomyositis, Endometrial Cancer, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Hairy Cell Leukemia, Hidradenitis Suppurativa, Hypopharyngeal Cancer, Inflammation, Inflammatory Bowel Disease, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Leiomyosarcoma, Lupus Erythematosus, Lupus Nephritis, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Prostate Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Myelofibrosis, Myxoid Liposarcoma, Non-Hodgkin Lymphoma, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Plaque Psoriasis (Psoriasis Vulgaris), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Sicca Syndrome (Sjogren), Skin Cancer, Spondyloarthritis (Spondyloarthropathy), Synovial Sarcoma, Systemic Lupus Erythematosus, Thalassemia, Thrombocythemia Myelofibrosis, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Uveitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)

  • The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics



Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Han Wha Pharma Co Ltd
  • Japan Tobacco Inc
Introduction
Report Coverage
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
Aclaris Therapeutics Inc
Astellas Pharma Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
CJ HealthCare Corp
Concert Pharmaceuticals Inc
Eli Lilly and Co
Galapagos NV
Han Wha Pharma Co Ltd
Incyte Corp
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
LEO Pharma A/S
Nissan Chemical Industries Ltd
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Theravance Biopharma Inc
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles
ABBV-599 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
abrocitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-1777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-0449 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-1480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-4205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baricitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-15314 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTP-543 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
delgocitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-52793 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-54707 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itacitinib adipate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-0184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NIP-565 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peficitinib hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06700841 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-20347 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SART-29 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDC-1801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDC-1802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-0302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK1 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK1 and JAK3 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Jak1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1473 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
upadacitinib tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YJC-50018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Nov 01, 2018: Incyte presents Itacitinib at the 60th Annual ASH meeting
Nov 01, 2018: Incyte provides data on ruxolitinib (Jakafi) at the 60th Annual ASH meeting
Nov 01, 2018: With availability of Olumiant (baricitinib), Lilly brings new oral treatment option for Canadians living with rheumatoid arthritis
Nov 01, 2018: Portola Pharmaceuticals to present new interim phase 2 results for Cerdulatinib during an oral session at the 60th American Society of Hematology (ASH) Annual Meeting
Oct 25, 2018: FDA grants priority review for Ruxolitinib (Jakafi) as a treatment for patients with acute graft-versus-host disease
Oct 23, 2018: AbbVie's Upadacitinib shows significant improvements in physical function, Pain and quality of life as a monotherapy in patients with Rheumatoid Arthritis in phase 3 patient-reported outcomes data
Oct 22, 2018: Positive trial results with Filgotinib in psoriatic arthritis and ankylosing spondylitis both published in The Lancet
Oct 22, 2018: Reistone Biopharma, a new Chinese biotech company ready to initiate its Ulcerative Colitis phase II clinical trial globally
Oct 22, 2018: Theravance Biopharma reports data from TD-1473 phase 1b four-week study in oral late-breaker presentation at UEG Week 2018
Oct 22, 2018: Positive phase 2b data for AbbVie's Upadacitinib show significant induction of clinical remission and response in patients with Ulcerative Colitis
Oct 20, 2018: Phase 3 data on Filgotinib in biologic-experienced Rheumatoid Arthritis to be presented at 2018 ACR/ARHP Annual Meeting
Oct 16, 2018: AbbVie to present data on Upadacitinib at UEG Week 2018
Oct 15, 2018: New data showcasing Lilly's growing commitment in Rheumatology to be featured at the ACR/ARHP Annual Meeting
Oct 10, 2018: Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018
Oct 08, 2018: AbbVie to provides update on Upadacitinib at the 2018 ACR/ARHP Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..3), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..4), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Products under Development by Companies, H2 2018 (Contd..4), H2 2018
Products under Development by Companies, H2 2018 (Contd..5), H2 2018
Products under Development by Companies, H2 2018 (Contd..6), H2 2018
Products under Development by Companies, H2 2018 (Contd..7), H2 2018
Products under Development by Companies, H2 2018 (Contd..8), H2 2018
Products under Development by Companies, H2 2018 (Contd..9), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AbbVie Inc, H2 2018
Pipeline by Aclaris Therapeutics Inc, H2 2018
Pipeline by Astellas Pharma Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by CJ HealthCare Corp, H2 2018
Pipeline by Concert Pharmaceuticals Inc, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Galapagos NV, H2 2018
Pipeline by Han Wha Pharma Co Ltd, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by Japan Tobacco Inc, H2 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018
Pipeline by LEO Pharma A/S, H2 2018
Pipeline by Nissan Chemical Industries Ltd, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by Portola Pharmaceuticals Inc, H2 2018
Pipeline by Sareum Holdings Plc, H2 2018
Pipeline by Theravance Biopharma Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018
Discontinued Products, H2 2018 (Contd..1), H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AbbVie Inc

  • Aclaris Therapeutics Inc

  • Astellas Pharma Inc

  • AstraZeneca Plc

  • Bristol-Myers Squibb Co

  • CJ HealthCare Corp

  • Concert Pharmaceuticals Inc

  • Eli Lilly and Co

  • Galapagos NV

  • Han Wha Pharma Co Ltd

  • Incyte Corp

  • Japan Tobacco Inc

  • Jiangsu Hengrui Medicine Co Ltd

  • LEO Pharma A/S

  • Nissan Chemical Industries Ltd

  • Pfizer Inc

  • Portola Pharmaceuticals Inc

  • Sareum Holdings Plc

  • Theravance Biopharma Inc

Note: Product cover images may vary from those shown